MedTrace Logo

Open Label Trial of Nissle 1917

NCT02276508 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-02-18

No results posted yet for this study

Summary

Nissle 1917 is an E. coli based probiotic used in the Europe for close to 100 years to treat gastrointestinal disorders and infections. The investigators will assess the safety and tolerability of this medication in Americans in a Phase 1 trial.

Conditions

Interventions

DRUG

E. coli Nissle 1917

Participants will all take E. coli Nissle 1917 orally administered medication for 30 days

Sponsors & Collaborators

  • Elizabeth Lucas

    lead OTHER

Principal Investigators

  • Venkata R Jayanthi, MD · Nationwide Children's Hospital

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-12-31
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02276508 on ClinicalTrials.gov